Eribulin in triple negative metastatic breast cancer: Critic interpretation of current evidence and projection for future scenarios

Laura Pizzuti, Eriseld Krasniqi, Giacomo Barchiesi, Marco Mazzotta, Maddalena Barba, Antonella Amodio, Gioia Massimiani, Fabio Pelle, Ramy Kayal, Enrico Vizza, Antonino Grassadonia, Silverio Tomao, Aldo Venuti, Teresa Gamucci, Paolo Marchetti, Clara Natoli, Giuseppe Sanguineti, Gennaro Ciliberto, Patrizia Vici

Research output: Contribution to journalReview articlepeer-review


Triple negative breast cancer (TNBC) is characterized by distinctive biological features that confer an aggressive clinical behavior. In TNBC patients, the absence of well-defined driver pathways such as hormonal receptor expression or hyperactivation of the human epidermal growth factor receptor 2 (HER2) significantly reduce the spectrum of therapeutic options, which are currently mainly confined to chemotherapy. Thus far, median overall survival for patients with metastatic TNBC is about 9-12 months with conventional cytotoxic agents. However, the heterogeneity recently revealed at a gene expression level inside the TNBC family may help inform therapeutic decisions concerning the use of chemotherapy and hopefully lead the way to novel targeted options that include immunotherapy. Eribulin, a halichondrin class antineoplastic drug, is currently recommended for treatment of HER2 negative metastatic or recurrent breast cancer (BC) previously exposed to anthracyclines and taxanes, also for patients with a TNBC. It is currently indicated from the second line of treatment. In this review, we aim to analyze a wide range of cumulated evidence on eribulin use in TNBC including preclinical studies, intervention and observational clinical trials. Data from the real-world setting and the emerging evidence increasingly substantiating the rationale for combinations with new generation treatment strategies, e.g., PARP-inhibitors, immune checkpoint inhibitors, will be also discussed.

Original languageEnglish
Pages (from-to)5903-5914
Number of pages12
JournalJournal of Cancer
Issue number24
Publication statusPublished - Jan 1 2019


  • Eribulin
  • Metastatic breast cancer
  • Triple negative subtype

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Eribulin in triple negative metastatic breast cancer: Critic interpretation of current evidence and projection for future scenarios'. Together they form a unique fingerprint.

Cite this